These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 17277961)

  • 21. Osteoclasts but not osteoblasts are affected by a calcified surface treated with zoledronic acid in vitro.
    Schindeler A; Little DG
    Biochem Biophys Res Commun; 2005 Dec; 338(2):710-6. PubMed ID: 16243296
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bisphosphonates--history and experimental basis.
    Fleisch H
    Bone; 1987; 8 Suppl 1():S23-8. PubMed ID: 3318890
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nitrogen-containing bisphosphonates inhibit isopentenyl pyrophosphate isomerase/farnesyl pyrophosphate synthase activity with relative potencies corresponding to their antiresorptive potencies in vitro and in vivo.
    van Beek E; Pieterman E; Cohen L; Löwik C; Papapoulos S
    Biochem Biophys Res Commun; 1999 Feb; 255(2):491-4. PubMed ID: 10049736
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vivo effects of bisphosphonates on the osteoclast mevalonate pathway.
    Fisher JE; Rodan GA; Reszka AA
    Endocrinology; 2000 Dec; 141(12):4793-6. PubMed ID: 11108295
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bisphosphonates, specific inhibitors of osteoclast function and a class of drugs for osteoporosis therapy.
    Li B; Ling Chau JF; Wang X; Leong WF
    J Cell Biochem; 2011 May; 112(5):1229-42. PubMed ID: 21465521
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The molecular basis of bisphosphonate activity: a preclinical perspective.
    Green J; Clézardin P
    Semin Oncol; 2010 Jun; 37 Suppl 1():S3-11. PubMed ID: 20682369
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular mechanisms of action of bisphosphonates: current status.
    Roelofs AJ; Thompson K; Gordon S; Rogers MJ
    Clin Cancer Res; 2006 Oct; 12(20 Pt 2):6222s-6230s. PubMed ID: 17062705
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Therapy of Paget's disease].
    Kurth AA
    Orthopade; 2007 Feb; 36(2):118, 120-3. PubMed ID: 17252256
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Bisphosphonates, their mechanism of action and properties useful in the therapy of metabolic bone diseases].
    Fojtík Z; Kandusová M
    Vnitr Lek; 1997 Apr; 43(4):234-7. PubMed ID: 9601843
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identifying Potential Therapeutics for Osteoporosis by Exploiting the Relationship between Mevalonate Pathway and Bone Metabolism.
    Hasan WNW; Chin KY; Jolly JJ; Ghafar NA; Soelaiman IN
    Endocr Metab Immune Disord Drug Targets; 2018; 18(5):450-457. PubMed ID: 29683099
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anti-resorptive therapies for osteoporosis.
    Reid IR
    Semin Cell Dev Biol; 2008 Oct; 19(5):473-8. PubMed ID: 18760372
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Denosumab and bisphosphonates: different mechanisms of action and effects.
    Baron R; Ferrari S; Russell RG
    Bone; 2011 Apr; 48(4):677-92. PubMed ID: 21145999
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bisphosphonates in osteoporosis: an introduction.
    Fleisch H
    Osteoporos Int; 1993; 3 Suppl 3():S3-5. PubMed ID: 8298201
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [The influence of bisphosphonates on fracture healing].
    Seebach C; Kurth A; Marzi I
    Orthopade; 2007 Feb; 36(2):136-40. PubMed ID: 17242960
    [TBL] [Abstract][Full Text] [Related]  

  • 35. How do bisphosphonates affect fracture healing?
    Kates SL; Ackert-Bicknell CL
    Injury; 2016 Jan; 47 Suppl 1(0 1):S65-8. PubMed ID: 26768295
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Bisphosphonates: the molecular targets and mechanisms of action].
    Wada S; Kamiya S; Ono K
    Clin Calcium; 2005 May; 15(5):819-24. PubMed ID: 15876745
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase.
    Bergstrom JD; Bostedor RG; Masarachia PJ; Reszka AA; Rodan G
    Arch Biochem Biophys; 2000 Jan; 373(1):231-41. PubMed ID: 10620343
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibition of the mevalonate pathway and activation of p38 MAP kinase are independently regulated by nitrogen-containing bisphosphonates in breast cancer cells.
    Merrell MA; Wakchoure S; Lehenkari PP; Harris KW; Selander KS
    Eur J Pharmacol; 2007 Sep; 570(1-3):27-37. PubMed ID: 17640631
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bisphosphonates: an overview with special reference to alendronate.
    Vasikaran SD
    Ann Clin Biochem; 2001 Nov; 38(Pt 6):608-23. PubMed ID: 11732644
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Aminobisphosphonates cause osteoblast apoptosis and inhibit bone nodule formation in vitro.
    Idris AI; Rojas J; Greig IR; Van't Hof RJ; Ralston SH
    Calcif Tissue Int; 2008 Mar; 82(3):191-201. PubMed ID: 18259679
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.